The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

(2020) Nikole J. Byrne et al.   Circulation-Heart Failure

BRCA1 Deficiency Impairs Mitophagy and Promotes Inflammasome Activation and Mammary Tumor Metastasis

(2020) Qiang Chen et al.   Advanced Science

Metabolic Plasticity in Chemotherapy Resistance

(2020) Maria Andrea Desbats et al.   Frontiers in Oncology

Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1

(2020) Zhenzhu Sun et al.   BIOCHEMICAL PHARMACOLOGY

Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment.

(2019) Claudia Tulotta et al.   CLINICAL CANCER RESEARCH

NLRP3 inflammasome inactivation driven by miR‑223‑3p reduces tumor growth and increases anticancer immunity in breast cancer

(2019) Liping Zhang et al.   Molecular Medicine Reports

Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring

(2019) Nadine Wenningmann et al.   MOLECULAR PHARMACOLOGY

Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome

(2019) Xueling Li et al.   Frontiers in Physiology

NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis

(2019) Nour Ershaid et al.   Nature Communications

Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated C-Reactive Protein

(2018) Cory Trankle et al.   AMERICAN JOURNAL OF CARDIOLOGY

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-1 drives breast cancer growth and bone metastasis in vivo

(2016) Ingunn Holen et al.   Oncotarget

NLRP3 Deficiency Reduces Macrophage Interleukin-10 Production and Enhances the Susceptibility to Doxorubicin-induced Cardiotoxicity

(2016) Motoi Kobayashi et al.   Scientific Reports

Targeting inflammasome/IL-1 pathways for cancer immunotherapy

(2016) Beichu Guo et al.   Scientific Reports

The Importance of NLRP3 Inflammasome in Heart Failure

(2015) Brittany Butts et al.   JOURNAL OF CARDIAC FAILURE

Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse

(2015) Carlo Marchetti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

(2014) Shiwei Deng et al.   BMC CANCER

Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs

(2014) John Wong et al.   CANCER BIOLOGY & THERAPY

Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

(2014) Alix E. Seif et al.   PEDIATRIC BLOOD & CANCER

A Novel Pharmacologic Inhibitor of the NLRP3 Inflammasome Limits Myocardial Injury After Ischemia–Reperfusion in the Mouse

(2013) Carlo Marchetti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Inflammasomes in health and disease

(2012) Till Strowig et al.   NATURE

Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity

(2011) Jinzhou Zhu et al.   BIOMEDICINE & PHARMACOTHERAPY

Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome

(2011) Kristin A. D. Sauter et al.   CANCER BIOLOGY & THERAPY

Discovery of IL-18 As a Novel Secreted Protein Contributing to Doxorubicin Resistance by Comparative Secretome Analysis of MCF-7 and MCF-7/Dox

(2011) Ling Yao et al.   PLoS One

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse

(2011) E. Mezzaroma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity

(2010) Jinzhou Zhu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Doxorubicin Cardiomyopathy

(2009) Kanu Chatterjee et al.   CARDIOLOGY

The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis

(2009) Luigi Franchi et al.   NATURE IMMUNOLOGY